02.10.2017 • NewsDede WillamsBluestarAsahi Kasei

Asahi Kasei and Bluestar Studying mPPE

(c) mmmx/Shutterstock
(c) mmmx/Shutterstock

Japan’s Asahi Kasei and China’s Bluestar, a ChemChina subsidiary, have agreed to study the economics of building production facilities for producing a modified polyphenylene ether (mPPE) in China.

The facilities would include the intermediates 2,6-xylenol and polyphenylene ether (PPE). Following completion of detailed feasibility studies, the companies plan to make a final investment decision by March 2018.

The plans will be realized by a joint venture agreed in February of this year and will leverage Bluestar’s technology for 2,6-xylenol and PPE in combination with Asahi Kasei’s mPPE compounding technology and applications development capability.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.